Article
A retrospective analysis of the ACR RISE registry shows that multimorbidity is not only common in patients with active rheumatoid arthritis (RA), but also impacts treatment choices and outcomes.
All News
Article
Randomized clinical trials in primary Sjögren's syndrome (pSS) are fraught with fault and inconclusive outcome measures, including the more recently developed EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). There's a new composite endpoint outcome for RCTs in pSS, called the Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS).
Article
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
Article
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Dr. John Cush
Tweet
CRESS – A New Composite Measure for Primary Sjögren's Syndrome
https://t.co/7tvjBvP3g4
Dr. John Cush
Tweet
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
https://t.co/6Dfdnin1aI
Dr. John Cush
Tweet
Cohort study of 66 874 postmenopausal women older than 50 years finds fracture to predict a greater risk of subsequent fracture (regardless whether 1st fracture was traumatic or nontraumatic). All such pts need OP assessments https://t.co/EQtDdZb8Vz
Dr. John Cush
Tweet
Systematic review of Kawasaki Dz treatment (4 RCTs, 456 pts) shows MAb & anti-cytokine biologic use does not reduce Coronary artery abnormalities (RR 0.93; [95%CI], 0.65 to 1.32) vs IVIG, but Abs did reduce Rx resistence (RR 0.60) https://t.co/FJkQfxCkjB
Dr. John Cush
Tweet
Congrats to Deborah Veis, MD, PhD, appointed to be the next editor-in-chief of Journal of Bone & Mineral Research Plus (JBMR Plus). Dr Veis is a professor in the Division of Bone & Mineral Diseases at Washington University School of Medicine https://t.co/9aOibSdhqC
Dr. John Cush
Tweet
JRheum review: 40–50% of psoriasis pts have psoriatic nail disease NP). NP is an important predictor of enthesitis, which is associated with the early stages of PsA https://t.co/sEuih3CSgX
Dr. John Cush
Tweet
ICYMI: FDA Approves IVIG in Dermatomyositis
https://t.co/PoHtzDYekk
The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/eAQa2oPOOf
Dr. John Cush
Tweet
Hands-Down Rheumatology - Sarcoidosis usually presents as a monarthritis or oligoarthritis. Late sarcoid arthritis affects knees, ankles, fingers (dactylitis). Bony lesions show honeycomb trabecular pattern).
https://t.co/85zvhk4Poz https://t.co/pb9ABL5O8a
Dr. John Cush
Tweet
ICYMI: Potential Birth Defects with Hydroxychloroquine
HCQ is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.
https://t.co/k1LOQvWlVm https://t.co/Ka96e733rp
Dr. John Cush
Tweet
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
https://t.co/6Dfdnin1aI https://t.co/rJFn9WuCgO
Dr. John Cush
Tweet
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the FDA for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
https://t.co/22HVA32IAh https://t.co/xZNfepcDLQ
k dao
Tweet
Don't forget to register for the ACR Virtual Townhall Wednesday 8/4/21: 7 PM ET
Re: COVID vaccination effectiveness for rheum patients w/real world data
@ACRheum @alhkim @rheum_cat
https://t.co/CKAwSLMv8R
Dr. John Cush
Tweet
"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.
https://t.co/uv19GSZsBV https://t.co/aSFlV9zeGt
Seminars in Arthritis and Rheumatism
Tweet
Article in press:
Can ANCA titers predict relapse in patients with GPA?
Cohort study by @UofT_DoM
- microscopic hematuria and MPO ab at month 12 predicted increased risk of relapse
https://t.co/ks3Gj5iSLR
Dr. John Cush
Tweet
Study from the UK BSRBR for #AS & 2043 pts showed 44% w/ at least 1 comorbidity. Each comorbidity was associated w/ 0.40 unit increase in BASDAI and 0.53 in spinal pain. More Dz activity w/ Depression, CHF and peptic ulcer, not CRP/ESR https://t.co/0vAnbjHicw
Dr. John Cush
Tweet
FDA Approves Anifrolumab in active, moderate-severe SLE on background standard of care therapies. https://t.co/22HVA32IAh https://t.co/NxJ4sWTWfE
